FluoGuide Strengthens Leadership to Drive Clinical and Regulatory Advancements

FluoGuide, a biotech company specializing in precision cancer surgery, has made significant changes to its leadership and board to support its transition into late-stage U.S. clinical development and regulatory approval for its lead product FG0011.

Donna Haire has been appointed as full-time Chief Operating Officer, bringing over 30 years of global experience in R&D, regulatory affairs, and clinical development1. She steps down from the Board of Directors to focus on operational leadership.

Donna Haire’s past roles include senior leadership at On Target Laboratories, Bayer, AngioDynamics, Philips Healthcare, Medtronic, and the Cleveland Clinic Foundation. She also holds positions on boards of Sedana Medical AB and BioPorto A/S, and has been active in regulatory and academic circles1.

To replace Haire on the Board of Directors, FluoGuide proposes electing Camilla Harder Hartvig, a leader with over 30 years’ international commercial and operational experience in the life science sector1.

Camilla Harder Hartvig previously served as EVP & Chief Commercial Officer at Ascendis Pharma and Theramex, and as Senior VP at Alexion Pharmaceuticals, contributing to global product launches at AstraZeneca1.

These leadership changes are intended to add complementary development, regulatory, and commercial expertise as FluoGuide advances FG001 toward its first US approval and plans for future commercialization13.

An extraordinary general meeting is scheduled for November 24, 2025, to formally elect Camilla Harder Hartvig to the Board of Directors and address authorization of new share issues3.

Sources:

1. https://www.biospace.com/press-releases/fluoguide-strengthens-leadership-to-advance-clinical-program-and-regulatory-approval-strategy

3. https://www.morningstar.com/news/accesswire/1097357msn/fluoguide-convenes-an-extraordinary-general-meeting